Nomination proposal strengthens Idogen’s Board within cell therapy and drug development
Prior to the Idogen AB (publ) Annual General Meeting of 17 May 2017, the Nomination Committee has presented its proposal for a new Board. Chairman of the Board Agneta Edberg is proposed to be re-elected and re-election is also proposed for Board members Leif G. Salford and Ulf Blom. The Board members Cecilia Hollerup and Mikael Ørum have declined re-election and new Board members, Christina Herder and Karin Hoogendoorn, are proposed.
The Nomination committee, representing Idogen’s largest shareholders, proposes that the Board of Directors consist of five ordinary members without alternates until the end of the next Annual General Meeting. The Nomination Committee furthermore proposes remuneration to be issued by SEK 300,000 per year to the Chairman of the Board and with each SEK 150,000 per year to the ordinary Board members.
“Idogen now enters a new phase and the Nomination Committee has attached great importance to nominate a Board whose competence is adapted to the next step in the company’s development, which leads to the company being able to create new treatments for vulnerable patient groups. The company’s larger owners have chosen to step aside to strengthen the Board's competence in the production of cell therapy and later phases of pharmaceutical development.” The Chairman of the Nomination Committee Håkan Hollerup comments.
Christina Herder has over 20 years of experience in early phase drug development and business development in the pharmaceutical industry. Her previous assignments include several senior roles in among other Swedish Orphan Biovitrum AB (Sobi) and Biovitrum. The last three years Christina has been CEO of Modus Therapeutics, a Swedish drug development company. Since 2015 she has been a member of the Board of PCI Biotech Holding ASA (listed on Oslo Axess). Christina Herder holds a doctorate from the Royal Institute of Technology in Stockholm and an executive MBA from Stockholm University.
Karin Hoogendoorn has significant experience in pharmaceutical product development of cell based medicinal products and the special regulations that apply to these and other advanced therapies (ATMPs). She has previously been appointed as Associate Director of Global Regulatory Affairs-CMC Cell & Gene Therapy Products at Novartis AG, Basel, Switzerland and Associate Director Global Regulatory Affairs-CMC at Janssen Biologics BV, Leiden, the Netherlands, and is currently Head of CMC at Immunicum AB (publ). Karin Hoogendoorn holds a Pharm.D. degree from Utrecht University, the Netherlands.
Of the Board members proposed by the Nomination Committee, Agneta Edberg, Ulf Blom, Christina Herder and Karin Hoogendoorn are independent of the company, the company management and major shareholders in the Company. The Annual General Meeting of Idogen AB will be held on 17th of May 2017 at. 15.00 in “Gamla Gästmatsalen” at Medicon Village, Scheelevägen 2, Lund. The Nomination Committee for the Annual General Meeting consisted of Håkan Hollerup (chairman), representing HCN Group AB, Mikael Ørum, representing Ventac Holdings (Cyprus) Limited, and Leif G. Salford. The Chairman of the Board, Agneta Edberg, has been adjunct to the Nomination Committee.
For additional information, please contact:
Lars Hedbys, CEO
Tel: 46 - 46 - 275 63 30
E-mail: lars.hedbys@idogen.com
Idogen develops tolerogenic vaccines which re-program the immune system. The term "tolerogenic" refers to that the immune system will tolerate the selected molecule after treatment. It represents a new treatment method for autoimmune diseases, organ rejection after transplantation and patients without treatment after developing antibodies against standard treatment. The first indication for the therapy will be patients with the bleeding disorder hemophilia A who have developed an immunological reaction against their necessary factor VIII replacement.
The treatment method comprises cells from the patient's blood being reprogrammed to dendritic cells with the capacity to specifically counteract the adverse immune reaction. The company's technology platform has the potential to develop long-acting treatment of anti-drug antibodies as well as autoimmune diseases that currently cannot be cured. In addition, Idogen has the potential to change the transplantation market by reducing the need for immunosuppressive therapy after transplantation. Idogen was founded in 2008 based on a fundamental immunological discovery at Lund University. For more information, visit www.idogen.com
Tags: